Supplier
Medical Solution NP Corp
Medical Solution NP Corp was paid $270K by Medicaid between Dec 2021 and Feb 2023, across 11 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 32% of everything it billed.
33Billing provider infoMEDICAL SOLUTION NP CORP
NEW YORK, NY 10034
NEW YORK, NY 10034
33aNPI1861092405assigned 10/30/2020
33bProvider typeDurable Medical Equipment & Medical Supplies
28Total paid$270K
24GClaims21,205
24DCodes billed11
24AFirst – last monthDec 2021 – Feb 2023
Compared with peers
Next to other Durable Medical Equipment & Medical Supplies providers in New York
Rank by total paid#199 of 479
Median peer was paid$138K
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 1,680 | $21K | |
| 2022 | 19,194 | $243K | |
| 2023 | 331 | $6K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 32% | 2,578 | 2,438 | $87K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 18% | 2,178 | 2,010 | $48K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 13% | 1,389 | 1,332 | $36K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 13% | 3,606 | 3,151 | $36K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 10% | 4,526 | 4,039 | $28K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 8.6% | 1,691 | 1,400 | $23K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.8% | 57 | 47 | $8K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,766 | 4,240 | $3K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 319 | 298 | $427.90 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 82 | 82 | $12.56 |
| 99000 | 0% | 13 | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFIELDS, NORMAN (PRESIDENT)